GlassScriptPhysician profile
Gil Guedes
NPI 1093164147
$4,909.06
in general payments reported to CMS, 2019-2025
9 companies · $935 in 2025
The $935 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $282 · 2021: $771 · 2022: $461 · 2023: $984 · 2024: $821 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,739.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,449.65 | 2020-2025 | Hydrus Microstent, Precision7, Total30 |
| Johnson & Johnson Vision Care, INC. | $1,321.49 | 2019-2025 | Acuvue |
| Coopervision INC. | $871.02 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $557.09 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $229.26 | 2022-2025 | Biotrue One Day, Infuse |
| Sun Pharmaceutical Industries INC. | $213.63 | 2024-2025 | |
| Ivantis, INC | $133.71 | 2020 | |
| Lombart Brothers, INC. | $90.90 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $42.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gil Guedes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.